EP2334302B1 - Dosage forms for weakly ionizable compounds - Google Patents

Dosage forms for weakly ionizable compounds

Info

Publication number
EP2334302B1
EP2334302B1 EP09792369.2A EP09792369A EP2334302B1 EP 2334302 B1 EP2334302 B1 EP 2334302B1 EP 09792369 A EP09792369 A EP 09792369A EP 2334302 B1 EP2334302 B1 EP 2334302B1
Authority
EP
European Patent Office
Prior art keywords
dosage forms
ionizable compounds
weakly ionizable
weakly
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
EP09792369.2A
Other languages
German (de)
French (fr)
Other versions
EP2334302A2 (en
Inventor
Vikas Agarwal
Sami M Nazzal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cima Labs Inc
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of EP2334302A2 publication Critical patent/EP2334302A2/en
Application granted granted Critical
Publication of EP2334302B1 publication Critical patent/EP2334302B1/en
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
EP09792369.2A 2008-09-09 2009-09-09 Dosage forms for weakly ionizable compounds Withdrawn - After Issue EP2334302B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9549308P 2008-09-09 2008-09-09
US16199209P 2009-03-20 2009-03-20
PCT/US2009/056362 WO2010030667A2 (en) 2008-09-09 2009-09-09 Dosage forms for weakly ionizable compounds

Publications (2)

Publication Number Publication Date
EP2334302A2 EP2334302A2 (en) 2011-06-22
EP2334302B1 true EP2334302B1 (en) 2018-03-21

Family

ID=41667166

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09792369.2A Withdrawn - After Issue EP2334302B1 (en) 2008-09-09 2009-09-09 Dosage forms for weakly ionizable compounds

Country Status (5)

Country Link
EP (1) EP2334302B1 (en)
JP (1) JP5661630B2 (en)
CA (1) CA2735660C (en)
MX (1) MX340669B (en)
WO (1) WO2010030667A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201709388QA (en) * 2013-04-05 2017-12-28 Scpharmaceuticals Inc Pharmaceutical formulations for subcutaneous administration of furosemide
CN108295264A (en) * 2018-03-28 2018-07-20 五邑大学 The application of polyvinylpyrrolidone k12
EP3906019A1 (en) 2019-01-04 2021-11-10 SQ Innovation AG Pharmaceutical compositions of furosemide and uses thereof
MA54865A (en) 2019-01-31 2022-05-04 Scpharmaceuticals Inc CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDE AND METHODS OF ADMINISTRATION THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613332B1 (en) * 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
CA2339991C (en) * 1998-08-13 2007-01-02 Cima Labs Inc. Microemulsions as solid dosage forms for oral administration
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
AU1548001A (en) * 1999-11-24 2001-06-04 Wakamoto Pharmaceutical Co., Ltd. Ophthalmic aqueous preparation
EP1361866A4 (en) * 2001-02-23 2007-10-17 Cima Labs Inc Emulsions as solid dosage forms for oral administration
DE102004021281A1 (en) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam formulations in veterinary medicine

Also Published As

Publication number Publication date
JP2012502065A (en) 2012-01-26
WO2010030667A2 (en) 2010-03-18
CA2735660C (en) 2017-05-30
EP2334302A2 (en) 2011-06-22
MX340669B (en) 2016-07-20
JP5661630B2 (en) 2015-01-28
MX2011002084A (en) 2011-03-29
WO2010030667A3 (en) 2010-07-22
CA2735660A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
ZA201104336B (en) Pharmaceutical compounds
GB0816372D0 (en) Pharmaceutical compounds
GB0820819D0 (en) Pharmaceutical compounds
GB0801416D0 (en) Pharmaceutical compounds
ZA201006029B (en) Pharmaceutical dosage form
EP2320907A4 (en) Therapeutic compounds
IL209895A0 (en) Compounds for treating beta-amyloidoses
GB0816371D0 (en) Pharmaceutical compounds
IL200020A0 (en) Dosage regimen for comt inhibitors
EP2268285A4 (en) Therapeutic compounds
GB0806794D0 (en) Therapeutic compounds
GB0813740D0 (en) Therapeutic compounds
GB0812969D0 (en) Pharmaceutical compounds
ZA200903858B (en) Pharmaceutical dosage form
PL2271618T3 (en) Pharmaceutical compounds
GB0816370D0 (en) Pharmaceutical compounds
GB0804755D0 (en) Therapeutic compounds
GB0810857D0 (en) Pharmaceutical compounds
EP2334302B1 (en) Dosage forms for weakly ionizable compounds
EP2285385A4 (en) siRNA COMPOUNDS FOR INHIBITING NRF2
EP2265260A4 (en) Solid dosage form for treating headaches
HK1156250A1 (en) Unit dosage of apadenoson
PT2519233E (en) Pharmaceutical composition for treating alcohol dependency
GB0908905D0 (en) Pharmaceutical compounds
EP2276769A4 (en) New peptidomimetic compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110411

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1158980

Country of ref document: HK

17Q First examination report despatched

Effective date: 20161007

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20171011

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

PUAC Information related to the publication of a b1 document modified or deleted

Free format text: ORIGINAL CODE: 0009299EPPU

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: PK

Free format text: DIE ERTEILUNG WURDE VOM EPA WIDERRUFEN.

DB1 B1 document deleted

Effective date: 20180302

18W Application withdrawn

Effective date: 20180222

REG Reference to a national code

Ref country code: LU

Ref legal event code: HK

Effective date: 20180328

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 980352

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009051381

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R107

Ref document number: 602009051381

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REZ

Ref document number: 980352

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180321

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: DAS LOESCHDATUM WURDE ERGAENZT / LE CHAMP DATE DE RADIATION A ETE COMPLETE / LA DATA DI CANCELLAZIONE E STATA COMPLETATA